What happened
FDA reviewed records submitted by Babikian Healthcare Products CJSC in response to an August 12, 2025 request and identified significant CGMP violations involving its OTC drug manufacturing operations. The firm did not test the identity of each incoming component or validate the reliability of suppliers’ certificates of analysis at appropriate intervals. FDA also found no evidence that specified active ingredients met referenced USP limits. Finished-product reports lacked appropriate assay testing for active-ingredient identity and strength and for impurities; records also failed to demonstrate adequate microbiological testing for each batch before release. FDA stated that the quality unit did not adequately exercise its authority and responsibilities. It failed to ensure written production and process-control procedures for process performance and qualification of a system producing a component, complete manufacturing information in batch records, stability data supporting labeled expiration dates, and adequate quality-unit authority and procedures. FDA characterized the quality systems as inadequate and stated that the drug products were adulterated because manufacturing methods, facilities, or controls did not conform to CGMP.
Why it matters
From a GMP perspective, absent incoming-material identity testing and periodic verification of supplier results, the firm lacks scientific evidence that components meet specifications before use, as FDA stated. Inadequate finished-product chemical and microbiological testing similarly limits assurance that released batches have the intended identity, strength, purity, and microbiological quality. Weak quality-unit oversight, incomplete batch information, insufficient qualification controls, and unsupported expiration dating may undermine consistent manufacturing control and the ability to demonstrate product quality.
Key topics: Missing incoming-component identity testing and supplier certificate verification, Inadequate finished-product assay, impurity, and microbiological testing, Quality-unit failures involving process qualification, batch records, and stability support